AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine for the Adjunctive Treatment of Major Depressive Disorder Pharmaceutical Investing
Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia in Patients with Moderately to Severely Active Ulcerative Colitis Pharmaceutical Investing
Potent Ventures Appoints Seasoned Chief Marketing Officer in Preparation for Launch of the Gummy Project Resource Investing
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma Pharmaceutical Investing
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor Pharmaceutical Investing
BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer Life Science Investing
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy Pharmaceutical Investing
